Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)

Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong Wook Song, Yi Hsing Chen, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Yoshihiro Nakashima, Teruaki Shiomi, Emi Yamada

研究成果: Comment/debate査読

抄録

Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.

本文言語English
論文番号155
ジャーナルArthritis Research and Therapy
22
1
DOI
出版ステータスPublished - 2020 6 23

ASJC Scopus subject areas

  • リウマチ学
  • 免疫アレルギー学
  • 免疫学

フィンガープリント

「Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル